{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:39:45Z","timestamp":1789011585632,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"am","delay-in-days":285,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08 CA230172"],"award-info":[{"award-number":["K08 CA230172"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.leukres.2021.106569","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T21:57:40Z","timestamp":1617227860000},"page":"106569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy"],"prefix":"10.1016","volume":"106","author":[{"given":"Jacob L.","family":"Glass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-8493","authenticated-orcid":false,"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hilden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2558-1353","authenticated-orcid":false,"given":"Katya","family":"Ahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Kishtagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Douer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2021.106569_bib0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.beha.2008.12.007","article-title":"The coagulopathy of acute promyelocytic leukaemia revisited","volume":"22","author":"Stein","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"13","key":"10.1016\/j.leukres.2021.106569_bib0010","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1182\/blood-2016-10-747170","article-title":"Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era","volume":"129","author":"Mantha","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2021.106569_bib0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.leukres.2021.106569_bib0020","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2010-02-269621","article-title":"Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710","volume":"116","author":"Powell","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2021.106569_bib0025","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2012-02-410746","article-title":"All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)","volume":"120","author":"Iland","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2021.106569_bib0030","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.leukres.2013.05.007","article-title":"Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death","volume":"37","author":"Altman","year":"2013","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.leukres.2021.106569_bib0035","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2021.106569_bib0040","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMc1513710","article-title":"Targeted Therapy alone for acute promyelocytic leukemia","volume":"374","author":"Lo-Coco","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.leukres.2021.106569_bib0045","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/AAC.31.3.361","article-title":"Acyclovir prophylaxis for herpes simplex virus infection","volume":"31","author":"Gold","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.leukres.2021.106569_bib0050","series-title":"Oxford Handbook of Critical Care","author":"Singer","year":"2009"},{"issue":"3","key":"10.1016\/j.leukres.2021.106569_bib0055","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1080\/10428194.2020.1838507","article-title":"Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia","volume":"62","author":"Freyer","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.leukres.2021.106569_bib0060","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jaad.2005.07.030","article-title":"Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge","volume":"53","author":"Au","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.leukres.2021.106569_bib0065","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000353126","article-title":"High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia","volume":"131","author":"Yamakura","year":"2014","journal-title":"Acta Haematol."},{"issue":"3","key":"10.1016\/j.leukres.2021.106569_bib0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.leukres.2021.106569_bib0075","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00403-013-1367-0","article-title":"Role of regulatory T cells in patients with acute herpes zoster and relationship to postherpetic neuralgia","volume":"305","author":"Xing","year":"2013","journal-title":"Arch. Dermatol. Res."},{"issue":"1\u20132","key":"10.1016\/j.leukres.2021.106569_bib0080","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tox.2012.05.025","article-title":"Inorganic arsenic impairs proliferation and cytokine expression in human primary T lymphocytes","volume":"300","author":"Morzadec","year":"2012","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.leukres.2021.106569_bib0085","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10875-009-9280-1","article-title":"Effect of arsenic on regulatory T cells","volume":"29","author":"Hernandez-Castro","year":"2009","journal-title":"J. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.leukres.2021.106569_bib0090","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-017-07271-z","article-title":"Arsenic exposure impels CD4 commitment in thymus and suppress T cell cytokine secretion by increasing regulatory T cells","volume":"7","author":"Gera","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.leukres.2021.106569_bib0095","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Clinical practice. Herpes zoster","volume":"347","author":"Gnann","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2021.106569_bib0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621000709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621000709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:36:43Z","timestamp":1778668603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621000709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":20,"alternative-id":["S0145212621000709"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106569","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106569"}}